- New therapy tricks the immune system into thinking cancer is a virus
- Detecting the invading ‘virus’ the body then mounts an attack on disease
- Tested on 3 patients with melanoma – deadliest form of skin cancer
- In each case, strong immune response against the cancer was seen
Lizzie Parry For Dailymail.com
14
View
comments
Tricking the immune system into viewing cancer as an invading virus could lead scientists to the holy grail of a universal tumour vaccine, research suggests.
A first step towards the revolutionary new therapy has already been taken by researchers who tested it on three patients with melanoma, the deadliest form of skin cancer.
In each case, strong immune responses against the cancer were seen, although the early stage trial was not designed to measure the treatment’s effectiveness.
The approach involves taking the genetic instructions for a specific cancer protein, encoded in a molecule of RNA, and using it to stimulate the immune system.
Scientists at the University of Mainz in Germany have taken an important step towards creating a univeral cancer vaccine, which tricks the immune system into thinking cancer is an invading virus, thus causing the immune system to mount an attack on the disease
The RNA triggers the kind of immune response normally employed to see off viruses – only in this case, the targets are cancer cells.
The German research raises the possibility of a vaccine that can be tailored for any kind of cancer, or even new versions of a disease that evolve as it progresses within the same patient.
Writing in the journal Nature, the scientists led by Professor Ugur Sahin, from Johannes Gutenberg University in Mainz, Germany, concluded: ‘Virtually any tumour antigen (protein) can be encoded by RNA.
-
Forget about fats – it’s PROCESSED food we should be worried…
Smoking weed can make your teeth fall out: Long-term…
Pickle juice, brunch and a shot of vitamin C WILL help, but…
Women trying quit smoking should stop in the second half of…
‘Thus, the nanoparticulate RNA immunotherapy approach introduced here may be regarded as a universally applicable novel vaccine class for cancer immunotherapy.’
RNA is a molecular cousin of DNA and used to transfer genetic code instructions to protein-making machinery in cells.
To make their vaccine, the scientists created artificial nanoparticle ‘cells’ consisting of RNA surrounded by a fatty lipid membrane.
Various RNA sequences were used, representing a range of different cancer proteins, in experiments both involving mice and human patients.
Injected into the bloodstream, the RNA-lipoplex nanoparticles activated immune system dendritic cells in the lymph nodes and spleen.
Dendritic cells ‘flag up’ target proteins to immune system T-cells, thereby priming them to recognise and attack anything else carrying the same molecules. In this way, T-cells were turned against cancer tumours.
Powerful anti-cancer immune responses were seen in the melanoma patients involving both ‘helper’ T-cells which play a role in the production of antibodies, and ‘killer’ T-cells that actively destroy invaders.
Researchers have tested it on three patients with melanoma (pictured under the microscope), the deadliest form of skin cancer. In each case, strong immune responses against the cancer were seen, although the early stage trial was not designed to measure the treatment’s effectiveness
Cancer vaccines hold out great promise but are difficult to develop for a variety of reasons.
One obstacle is that the immune system is designed to avoid causing collateral damage to the body wherever possible.
Often cancer cells look too much like normal cells, and are therefore left alone or attacked only weakly.
Many cancers that have co-evolved with the immune system have developed ways of shielding themselves from it.
New immunotherapy drugs now being made available to patients are designed to take the brakes off the immune system so that cancer cannot escape. However, they can have unwanted side effects.
Commenting on the new research in Nature, cancer experts Professor Jolanda de Vries and Professor Carl Figdor, from Radboud University in the Netherlands, wrote: ‘This nanomedicine platform may give a strong boost to the vaccine field, and the results of forthcoming clinical studies will be of great interest.’
Professor Alan Melcher, from the Institute of Cancer Research, said: ‘Although the research is very interesting, it is still some way away from being of proven benefit to patients.’
Share or comment on this article
-
Extended video of Harambe shows gorilla holding the boy’s…
-
Two Middle aged couples bust out in brawl over Costco…
-
Bronx man beats would-be rapist to death in graphic video
-
Gorilla carries a three-year-old to safety in 1996 incident
-
Giant alligator strolls casually across Florida golf course
-
Cincinnati zoo director defends decision to kill Harambe
-
Crazy road rage driver runs over motorcyclists with his car
-
Syrian army ‘capture’ topless ISIS executioner ‘The…
-
CCTV shows Karen Perez leaving a taqueria before her death
-
Bikini-clad woman squats her friend in viral video
-
Terrifying moment Arnold Schwarzenegger charged by elephant
-
Texas teacher accused of having sex with 13-year-old student
-
EXCLUSIVE: Parents-of-four whose son fell into zoo enclosure…
-
New video footage of Harambe shows the 400-pound gorilla…
-
Vicious brawl erupts between two middle-aged couples outside…
-
PICTURED: The three-year-old boy who fell into zoo’s gorilla…
-
Amber Heard’s dire finances revealed: Court documents show…
-
‘He didn’t beat his chest’: Animal expert says Harambe the…
-
Parents of four-year-old who caused Harambe the gorilla’s…
-
Woman, 21, and father-of-one, 22, die and FIFTY SEVEN others…
-
Husband who killed his wife’s would-be rapist is CHEERED as…
-
Parents of boy who fell into gorilla enclosure say their son…
-
Widow, 90, could lose home she has lived in for 70 years…
-
Is storm chasing out of control? Adrenaline junkies pictured…
Comments (14)
Share what you think
-
Newest -
Oldest -
Best rated -
Worst rated
The comments below have not been moderated.
The views expressed in the contents above are those of our users and do not necessarily reflect the views of MailOnline.
Find out now